/AARD

Aardvark Therapeutics Inc

AARD

$5.79USD↓-12.54%-0.83 today

MARKET CAP

126.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$6 – $6

52W RANGE

$3

$18

AI Summary

Stalk

Sell NowMedium

AARD has broken below its consolidation neckline in Stage 3 distribution, with EMAs rolling over and rising volume confirming the bearish resolve. Medium-term bias is firmly bearish, anchored by a declining 200-day SMA and a double-top breakdown. Short-term conditions remain unfavourable for longs, so we sell now on this breakdown and look to re-engage only after potential pullbacks into former support zones.

↑Unique Prader-Willi niche; ARD-101 success could unlock unmet demand
↑$73.9M cash runway to late 2027; R&D spend cut to $10.5M
↓FDA’s full clinical hold halts ARD-101 HERO/OLE trials, delaying launch

Full analysis →

Buying

3

institutions

Selling

5

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
CA Citadel Advisors LLC Q2 2026	BUY	1.34 M	7.73 M	+46.59 K	+58.3%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	480.25 K	2.77 M	+345.75 K	+445.6%	0.00%
BI Blackrock, Inc. Q2 2026	SELL	187.04 K	1.08 M	+-605.53 K	-63.9%	0.00%
WP Woodline Partners LP Q2 2026	SELL	72.43 K	417.19 K	+-72.43 K	-23.6%	0.00%
MM Millennium Management LLC Q2 2026	SELL	69.95 K	402.90 K	+-28.39 K	+8.7%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUYNEW	22.87 K	131.74 K	+22.87 K	+0.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	1.78 K	9.24 K	+-4.83 K	-61.6%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	0.00	0.00	+-70.79 K	-100.0%	0.00%